23 April 2009
Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes
Maria JastrzebskaABDEFG, Kornel ChelstowskiBCDEF, Artur MierzeckiBEFG, Krzysztof KlimekABD, Hanna BukowskaBMed Sci Monit 2009; 15(5): PI27-33 :: ID: 869627
Abstract
Background
Patients with metabolic syndrome (MS) are characterized by enhanced procoagulant activity caused by an increased fibrinogen (Fb) level, impaired fibrinolysis, and platelet activation. Fibrate treatment usually normalizes these conditions. The aim was to determine the effect of fenofibrate treatment on Fb level, fibrinolysis, and platelet function in patients with MS with regard to smoking status and type 2 diabetes.
Material and Method
Sixty-four patients with MS, including 20 active smokers, without clinical features of coronary heart disease were enrolled in the study. Before and during treatment with fenofibrate all patients took antihypertensive drugs and 25 patients with type 2 diabetes used oral antidiabetic drugs. Before and after the treatment the levels of lipids, fasting glucose insulin, Fb, PAI-1, t-PA, and platelet function expressed as closure time (CT, after Coll/Epi and Coll/ADP) were measured.
Results
Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level. In smokers an increase in PAI-1 level and CT shortening after Coll/Epi and after Coll/ADP were found. In nonsmokers, CT was prolonged only after Coll/Epi. A slight reduction in PAI-1 and a reduction in fasting glucose were noted in the diabetics.
Conclusions
Fenofibrate partially corrected procoagulant state in patients with MS, which was manifested by a significant reduction in Fb level in all patients and inhibition of platelet function exclusively in nonsmokers. Smoking neutralizes the effects of treatment with fenofibrate as absence of inhibition of platelet function and a lack of improvement of the fibrinolysis system were observed in them.
Keywords: Thrombosis - physiopathology, Metabolic Syndrome X - physiopathology, Fenofibrate - therapeutic use, Smoking, Diabetes Mellitus, Type 2 - complications
Editorial
01 August 2022 : Editorial
Editorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 PandemicDOI: 10.12659/MSM.937927
Med Sci Monit 2022; 28:e937927
In Press
08 Aug 2022 : Clinical Research
A 3-Year Clinical Evaluation of Endodontically Treated Posterior Teeth Restored with Resin Nanoceramic Comp...Med Sci Monit In Press; DOI: 10.12659/MSM.937331
08 Aug 2022 : Clinical Research
Hemoglobin/Red Blood Cell Distribution Width Ratio in Peripheral Blood Is Positively Associated with Progno...Med Sci Monit In Press; DOI: 10.12659/MSM.937146
05 Aug 2022 : Clinical Research
A Retrospective Study of 98 Elderly Patients with High-Risk Lateral Femoral Wall Intertrochanteric Hip Frac...Med Sci Monit In Press; DOI: 10.12659/MSM.936923
04 Aug 2022 : Clinical Research
Radiological Assessment of Prevalance and Quality of Periapical Status of Endodontic TreatmentsMed Sci Monit In Press; DOI: 10.12659/MSM.936569
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996